Business
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. (\"Ensysce\" or the \"Company\") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB (\"OncoZenge\") (STO:ONCOZ), a clinical-stage company developing a transformative treatment for oral pain, are pleased to announce today that they have signed a letter of intent (LOI) to explore a strategic collaboration to accelerate the commercialization of BupiZenge™ in the United States.BupiZenge™ is OncoZenge's novel approach to treating pain caused by oral mucositis, an often severely debilitating condition of painful swelling and ulcerations of the mouth that commonly results from head and neck radiation and/or chemotherapy used to treat cancer. Left untreated, oral intake of food or fluids may be severely impeded and may adversely impact a patient's prognosis and quality of life.BupiZenge™ is a non-opioid oral formulation of the well-established local anesthetic bupivacaine. OncoZenge has successfully progressed BupiZenge™ through Phase 2 in the European Union (EU) and is currently in planning for the registrational Phase 3 program. Results from the Phase 2 study conducted in head and neck cancer patients with oral mucositis demonstrated strong efficacy in relieving pain with good safety and tolerability.The proposed collaboration aims to leverage the expertise and resources of both companies to accelerate the path to market in the United States for this innovative therapy that addresses critical unmet needs in the fields of analgesia and oncology.Stian Kildal, CEO of OncoZenge, commented, \"This collaboration aligns with our mission to enhance patient quality of life and provides a firm foundation for access to the important US market. In Ensysce we have found an experienced team that shares our passion and commitment to progress BupiZenge towards market approval. Together we have the potential to accelerate the introduction of our pain medication to those millions of patients who lack safe and effective treatment options under today's Standard of Care.\"\"We are thrilled to embark on this co-development with OncoZenge to further diver...